ATE95243T1 - Lymphotoxin, dafuer kodierende nukleinsaeure, die nukleinsaeure enthaltenden vektoren und damit transformierte zellen, verfahren zum erhalten von lymphotoxin und lymphotoxin neutralisierender antikoerper. - Google Patents

Lymphotoxin, dafuer kodierende nukleinsaeure, die nukleinsaeure enthaltenden vektoren und damit transformierte zellen, verfahren zum erhalten von lymphotoxin und lymphotoxin neutralisierender antikoerper.

Info

Publication number
ATE95243T1
ATE95243T1 AT85303818T AT85303818T ATE95243T1 AT E95243 T1 ATE95243 T1 AT E95243T1 AT 85303818 T AT85303818 T AT 85303818T AT 85303818 T AT85303818 T AT 85303818T AT E95243 T1 ATE95243 T1 AT E95243T1
Authority
AT
Austria
Prior art keywords
lymphotoxin
nucleic acid
obtaining
neutralizing antibodies
vectors containing
Prior art date
Application number
AT85303818T
Other languages
English (en)
Inventor
Bharat Bhushan Aggarwal
Patrick William Gray
Timothy Scott Bringman
Glenn Evan Nedwin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE95243T1 publication Critical patent/ATE95243T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT85303818T 1984-05-31 1985-05-30 Lymphotoxin, dafuer kodierende nukleinsaeure, die nukleinsaeure enthaltenden vektoren und damit transformierte zellen, verfahren zum erhalten von lymphotoxin und lymphotoxin neutralisierender antikoerper. ATE95243T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09
EP85303818A EP0164965B1 (de) 1984-05-31 1985-05-30 Lymphotoxin, dafür kodierende Nukleinsäure, die Nukleinsäure enthaltenden Vektoren und damit transformierte Zellen, Verfahren zum Erhalten von Lymphotoxin und Lymphotoxin neutralisierender Antikörper

Publications (1)

Publication Number Publication Date
ATE95243T1 true ATE95243T1 (de) 1993-10-15

Family

ID=27417179

Family Applications (2)

Application Number Title Priority Date Filing Date
AT85303818T ATE95243T1 (de) 1984-05-31 1985-05-30 Lymphotoxin, dafuer kodierende nukleinsaeure, die nukleinsaeure enthaltenden vektoren und damit transformierte zellen, verfahren zum erhalten von lymphotoxin und lymphotoxin neutralisierender antikoerper.
AT92110196T ATE195323T1 (de) 1984-05-31 1985-05-30 Anti-lymphotoxin-antikörper, herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92110196T ATE195323T1 (de) 1984-05-31 1985-05-30 Anti-lymphotoxin-antikörper, herstellung und verwendung

Country Status (23)

Country Link
EP (2) EP0509553B1 (de)
JP (3) JP2521703B2 (de)
AR (1) AR245219A1 (de)
AT (2) ATE95243T1 (de)
AU (1) AU599303B2 (de)
BG (1) BG60256B2 (de)
CA (1) CA1340641C (de)
CZ (1) CZ283148B6 (de)
DE (2) DE3587597T2 (de)
DK (1) DK171531B1 (de)
ES (1) ES8802182A1 (de)
FI (1) FI93025C (de)
GR (1) GR851317B (de)
HU (1) HU204085B (de)
IE (1) IE63487B1 (de)
IL (1) IL75318A (de)
NO (1) NO179075C (de)
NZ (1) NZ212207A (de)
PL (1) PL155410B1 (de)
PT (1) PT80573B (de)
RO (1) RO100383A2 (de)
SK (1) SK393085A3 (de)
YU (1) YU47735B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860001471B1 (ko) 1980-04-03 1986-09-26 비오겐 엔. 브이 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
ATE73856T1 (de) * 1984-12-21 1992-04-15 Biogen Inc Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230781B1 (de) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin-Gen, Verfahren zu dessen Herstellung und Lymphotoxin
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
EP0230574A3 (de) * 1986-01-31 1989-03-22 Yale University Pharmazeutische Zusammensetzungen gegen durch LAV/HTLV-III-Virus verursachte Infektionen und ihre Verwendung
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
JP2636862B2 (ja) * 1986-12-24 1997-07-30 武田薬品工業株式会社 組み換え型ヒトリンホトキシン
FI884798A (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (de) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispezifische hybride monoklonale Antikörper
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
DE69622157T2 (de) * 1995-01-23 2003-03-13 Xenotech Inc., Fremont Zusammensetzung zur verhinderung von osteolyse und metastasen
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
EP1572116A4 (de) * 2002-11-26 2007-12-12 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
AU2004252171B2 (en) 2003-06-27 2011-04-21 Biogen Ma Inc. Modified binding molecules comprising connecting peptides
US20050266004A1 (en) * 2003-12-08 2005-12-01 Jill Giles-Komar Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5298021B2 (ja) * 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
BR112016024841A2 (pt) * 2014-04-25 2017-10-24 Naurex Inc composições estáveis de peptídeos neuroativos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59007A (en) * 1978-12-22 1983-11-30 Biogen Nv Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production

Also Published As

Publication number Publication date
DE3588225D1 (de) 2000-09-14
PT80573A (en) 1985-06-01
EP0164965A3 (en) 1988-04-06
DE3588225T2 (de) 2001-04-05
RO100383A2 (ro) 1991-10-17
YU47735B (sh) 1996-01-08
IL75318A (en) 1994-08-26
EP0164965A2 (de) 1985-12-18
ATE195323T1 (de) 2000-08-15
NO179075C (no) 1996-07-31
SK278333B6 (en) 1996-11-06
PT80573B (pt) 1987-08-19
IL75318A0 (en) 1985-09-29
AU4320385A (en) 1985-12-05
BG60256B1 (bg) 1994-03-24
NO852173L (no) 1985-12-02
JPH07291995A (ja) 1995-11-07
CA1340641C (en) 1999-07-13
FI93025C (fi) 1995-02-10
FI93025B (fi) 1994-10-31
AR245219A1 (es) 1993-12-30
JPH07250692A (ja) 1995-10-03
DE3587597D1 (de) 1993-11-04
SK393085A3 (en) 1996-11-06
IE851321L (en) 1985-11-30
NO179075B (no) 1996-04-22
RO100383B1 (ro) 1991-03-01
CZ393085A3 (en) 1997-07-16
IE930589L (en) 1985-11-30
CZ283148B6 (cs) 1998-01-14
DK241385A (da) 1985-12-01
FI852143A0 (fi) 1985-05-29
ES543695A0 (es) 1988-04-16
JP2804237B2 (ja) 1998-09-24
JPS6156197A (ja) 1986-03-20
DK241385D0 (da) 1985-05-30
HUT37814A (en) 1986-02-28
EP0509553A1 (de) 1992-10-21
YU91985A (en) 1988-12-31
DE3587597T2 (de) 1994-06-01
BG60256B2 (bg) 1994-03-24
FI852143L (fi) 1985-12-01
EP0509553B1 (de) 2000-08-09
AU599303B2 (en) 1990-07-19
NZ212207A (en) 1991-07-26
EP0164965B1 (de) 1993-09-29
IE63487B1 (en) 1995-05-03
PL253739A1 (en) 1986-03-11
PL155410B1 (en) 1991-11-29
ES8802182A1 (es) 1988-04-16
DK171531B1 (da) 1996-12-23
HU204085B (en) 1991-11-28
GR851317B (de) 1985-11-25
JP2521703B2 (ja) 1996-08-07

Similar Documents

Publication Publication Date Title
ATE95243T1 (de) Lymphotoxin, dafuer kodierende nukleinsaeure, die nukleinsaeure enthaltenden vektoren und damit transformierte zellen, verfahren zum erhalten von lymphotoxin und lymphotoxin neutralisierender antikoerper.
DK110885A (da) Nucleinsyre-proteinkonjugater, disses anvendelse samt fremgangsmaade til fremstilling heraf
DE68918657D1 (de) Verfahren zum Nachweis spezifischer Nukleinsäuresequenzen.
DE3778355D1 (de) Verfahren zur entkeimung von mit lebenden zellen umgebenen oberflaechen.
DE3382359D1 (de) Verfahren zur kultivierung und isolierung von zellen.
DK58985A (da) Nukleinsyrereagenser, fremgangsmaade til fremstilling deraf og anvendelse deraf
DE3689412D1 (de) Verfahren zur durchführung von hybridisierungstests von nukleinsäuren.
DE68905267D1 (de) Halbleiteranordnung von metallhoecker-typ und verfahren zu deren herstellung.
DE3875061D1 (de) Hydroxamsaeuren-gruppen enhaltende polymere fuer die reduzierung von schwebenden festen koerpern in bayer-verfahren-stroemen.
DE3669952D1 (de) Verfahren zum herstellen von mos-transistoren mit metallsilicidelektroden.
DE3779268D1 (de) Glasgegenstand, hergestellt aus einem mit hilfe von gas geformten gel, und verfahren zum herstellen dieses gegenstandes.
DE3861164D1 (de) Verfahren zum herstellen von sphaerischen teilchen.
DE3578459D1 (de) Verfahren zur freund-oder-feind-abfrage und vorrichtung zur durchfuehrung dieses verfahrens.
DE3685368D1 (de) Hochfeste und hochzaehe stahlstaebe oder -draehte und verfahren zu deren herstellung.
DE3684654D1 (de) Elektrochemisches element und verfahren zu seiner herstellung.
DE69007993D1 (de) Verfahren zur Wiedergewinnung von Bromwasserstoffsäure und Methanol.
DE3579430D1 (de) Verfahren zur gewinnung von methacrylsaeure.
DE3578942D1 (de) Verfahren zum haerten von gelatine.
DE3574475D1 (de) Dextranhexonsaeureverbindung, komplex mit ferrihydroxyd und verfahren zu deren herstellung.
BR8104307A (pt) Sistema fotolitico para obtencao de produtos de oxidacao e reducao,e processo fotolitico para obtencao endotermica de produtos de oxidacao e reducao
DE3669591D1 (de) Verfahren und vorrichtung zur ermittlung der adhaesion von zellen.
DE3586161D1 (de) Verfahren zur synthese von ammoniak.
DE3671918D1 (de) Nukleinsaeure sequenzanalyse durch hemmung von exonuklease.
DE3578266D1 (de) Verfahren zum herstellen von halbleiteranordnungen und dadurch hergestellte anordnungen.
DE3689398D1 (de) Verfahren zum Extrahieren von Nukleinsäuren aus Zellen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time